Medication Guide App

Cleocin Phosphate

Generic Name: clindamycin phosphate
Dosage Form: injection, solution

Cleocin Phosphate®
(clindamycin injection, USP) and
(clindamycin injection in 5% dextrose )

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cleocin Phosphate and other antibacterial drugs, Cleocin Phosphate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

Sterile Solution is for Intramuscular and Intravenous Use

Cleocin Phosphate in the ADD-Vantage® Vial is For Intravenous Use Only

WARNING

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Cleocin Phosphate and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

Because Cleocin Phosphate therapy has been associated with severe colitis which may end fatally, it should be reserved for serious infections where less toxic antimicrobial agents are inappropriate, as described in the INDICATIONS AND USAGE section. It should not be used in patients with nonbacterial infections such as most upper respiratory tract infections. C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

Cleocin Phosphate Description

Cleocin Phosphate Sterile Solution in vials contains clindamycin phosphate, a water soluble ester of clindamycin and phosphoric acid. Each mL contains the equivalent of 150 mg clindamycin, 0.5 mg disodium edetate and 9.45 mg benzyl alcohol added as preservative in each mL. Clindamycin is a semisynthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent compound lincomycin.

The chemical name of clindamycin phosphate is L-threo-α-D-galacto-Octopyranoside, methyl-7-chloro-6,7,8-trideoxy-6-[[(1-methyl-4-propyl-2-pyrrolidinyl)carbonyl] amino]-1-thio-, 2-(dihydrogen phosphate), (2S-trans)-.

The molecular formula is C18H34CIN208PS and the molecular weight is 504.96.

The structural formula is represented below:

Cleocin Phosphate in the ADD-Vantage Vial is intended for intravenous use only after further dilution with appropriate volume of ADD-Vantage diluent base solution.

Cleocin Phosphate IV Solution in the Galaxy® plastic container for intravenous use is composed of clindamycin phosphate equivalent to 300, 600 and 900 mg of clindamycin premixed with 5% dextrose as a sterile solution. Disodium edetate has been added at a concentration of 0.04 mg/mL. The pH has been adjusted with sodium hydroxide and/or hydrochloric acid.

The plastic container is fabricated from a specially designed multilayer plastic, PL 2501. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period. The suitability of the plastic has been confirmed in tests in animals according to the USP biological tests for plastic containers, as well as by tissue culture toxicity studies.

Cleocin Phosphate - Clinical Pharmacology

Distribution

Biologically inactive clindamycin phosphate is converted to active clindamycin. By the end of short-term intravenous infusion, peak serum levels of active clindamycin are reached.

After intramuscular injection of clindamycin phosphate, peak levels of active clindamycin are reached within 3 hours in adults and 1 hour in pediatric patients. Serum level curves may be constructed from IV peak serum levels as given in Table 1 by application of elimination half-lives (see Excretion).

Serum levels of clindamycin can be maintained above the in vitro minimum inhibitory concentrations for most indicated organisms by administration of clindamycin phosphate every 8 to 12 hours in adults and every 6 to 8 hours in pediatric patients, or by continuous intravenous infusion. An equilibrium state is reached by the third dose.

No significant levels of clindamycin are attained in the cerebrospinal fluid even in the presence of inflamed meninges.

Excretion

Biologically inactive clindamycin phosphate disappears rapidly from the serum; the average elimination half-life is 6 minutes; however, the serum elimination half-life of active clindamycin is about 3 hours in adults and 2½ hours in pediatric patients.

Special Populations

Renal/Hepatic Impairment

The elimination half-life of clindamycin is increased slightly in patients with markedly reduced renal or hepatic function. Hemodialysis and peritoneal dialysis are not effective in removing clindamycin from the serum. Dosage schedules need not be modified in the presence of mild or moderate renal or hepatic disease.

Use in Elderly

Pharmacokinetic studies in elderly volunteers (61–79 years) and younger adults (18–39 years) indicate that age alone does not alter clindamycin pharmacokinetics (clearance, elimination half-life, volume of distribution, and area under the serum concentration-time curve) after IV administration of clindamycin phosphate. After oral administration of clindamycin hydrochloride, elimination half-life is increased to approximately 4.0 hours (range 3.4–5.1 h) in the elderly, compared to 3.2 hours (range 2.1– 4.2 h) in younger adults. The extent of absorption, however, is not different between age groups and no dosage alteration is necessary for the elderly with normal hepatic function and normal (age-adjusted) renal function1.

Serum assays for active clindamycin require an inhibitor to prevent in vitro hydrolysis of clindamycin phosphate.

Table 1. Average Peak and Trough Serum Concentrations of Active Clindamycin After Dosing with Clindamycin Phosphate
Dosage Regimen Peak
mcg/mL
Trough
mcg/mL
*
Data in this group from patients being treated for infection.
Healthy Adult Males
(Post equilibrium)
  600 mg IV in 30 min q6h 10.9 2.0
  600 mg IV in 30 min q8h 10.8 1.1
  900 mg IV in 30 min q8h 14.1 1.7
  600 mg IM q12h* 9.
Pediatric Patients (first dose)*
  5–7 mg/kg IV in 1 hour 10
  5–7 mg/kg IM 8
  3–5 mg/kg IM 4

Microbiology

Clindamycin inhibits bacterial protein synthesis by binding to the 50S subunit of the ribosome. It has activity against Gram-positive aerobes and anaerobes, as well as some Gram-negative anaerobes. Clindamycin is bacteriostatic. Cross-resistance between clindamycin and lincomycin is complete. Antagonism in vitro has been demonstrated between clindamycin and erythromycin. Clindamycin inducible resistance has been identified in macrolide-resistant staphylococci and beta-hemolytic streptococci. Macrolide-resistant isolates of these organisms should be screened for clindamycin inducible resistance using the D-zone test.

Clindamycin has been shown to be active against most of the isolates of the following microorganisms, both in vitro and in clinical infections, as described in the INDICATIONS AND USAGE section.

Gram-positive Aerobes

 
Staphylococcus aureus (methicillin-susceptible strains)
 
Streptococcus pneumoniae (penicillin-susceptible strains)
 
Streptococcus pyogenes

Anaerobes

 
Prevotella melaninogenica
 
Fusobacterium necrophorum
 
Fusobacterium nucleatum
 
Peptostreptococcus anaerobius
 
Clostridium perfringens

At least 90% of the microorganisms listed below exhibit in vitro minimum inhibitory concentrations (MICs) less than or equal to the clindamycin susceptible MIC breakpoint for organisms of a similar type to those shown in Table 2. However, the efficacy of clindamycin in treating clinical infections due to these microorganisms has not been established in adequate and well-controlled clinical trials.

Gram-positive aerobes

 
Staphylococcus epidermidis (methicillin-susceptible strains)
 
Streptococcus agalactiae
 
Streptococcus anginosus
 
Streptococcus oralis
 
Streptococcus mitis

Anaerobes

 
Prevotella intermedia
 
Prevotella bivia
 
Propionibacterium acnes
 
Micromonas ("Peptostreptococcus") micros
 
Finegoldia ("Peptostreptococcus") magna
 
Actinomyces israelii
 
Clostridium clostridioforme
 
Eubacterium lentum

Susceptibility Testing Methods

When available, the clinical microbiology laboratory should provide cumulative in vitro susceptibility test results for antimicrobial drugs used in local hospitals and practice areas to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting the most effective antimicrobial.

Dilution Techniques

Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure based on dilution methods (broth, agar or microdilution)2,3 or equivalent using standardized inoculum and concentrations of clindamycin. The MIC values should be interpreted according to the criteria provided in Table 2.

Diffusion Techniques

Quantitative methods that require the measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The standardized procedure2,4 requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 2 mcg of clindamycin to test the susceptibility of microorganisms to clindamycin. Reports from the laboratory providing results of the standard single-disk susceptibility test with a 2 mcg clindamycin disk should be interpreted according to the criteria in Table 2.

Table 2. Susceptibility Interpretive Criteria for Clindamycin
Susceptibility Interpretive Criteria
Pathogen Minimal Inhibitory Concentrations
(MIC in mcg/mL)
Disk Diffusion
(Zone Diameters in mm)
NA=not applicable

Staphylococcus spp.
S
≤ 0.5
I
1–2
R
≥4
S
≥21
I
15–20
R
≤14
Streptococcus pneumoniae and other Streptococcus spp. ≤0.25 0.5 ≥1 ≥19 16–18
≤15
Anaerobic Bacteria ≤2 4 ≥8 NA NA NA

A report of "Susceptible" indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of "Intermediate" indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone that prevents small, uncontrolled technical factors from causing major discrepancies in interpretation.

A report of "Resistant" indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.

Quality Control

Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of the supplies and reagents used in the assay, and the techniques of the individuals performing the test.2,3,4,5 Standard clindamycin powder should provide the MIC ranges in Table 3. For the disk diffusion technique using the 2 mcg clindamycin disk the criteria provided in Table 2 should be achieved.

Table 3. Acceptable Quality Control Ranges for Clindamycin to be Used in Validation of Susceptibility Test Results
Acceptable Quality Control Ranges
QC Strain Minimum Inhibitory Concentration Range
(mcg/mL)
Disk Diffusion Range
(Zone Diameters in mm)
NA=Not applicable
ATCC® is a registered trademark of the American Type Culture Collection
When Testing
Aerobic Pathogens
Staphylococcus aureus
ATCC 29213
0.06–0.25 NA
Staphylococcus aureus
ATCC 25923
NA 24–30
Streptococcus pneumoniae
ATCC 49619
0.03–0.12
19–25
When Testing
Anaerobes
Bacteroides fragilis
ATCC 25285
0.5–2 NA
Bacteroides thetaiotaomicron
ATCC 29741
2–8 NA
Eubacterium lentum
ATCC 43055
0.06–0.25 NA

Indications and Usage for Cleocin Phosphate

Cleocin Phosphate products are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria.

Cleocin Phosphate products are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin).

Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin.

Indicated surgical procedures should be performed in conjunction with antibiotic therapy.

Cleocin Phosphate is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below:

Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus.

Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes.

Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes.

Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms.

Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes.

Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cleocin Phosphate and other antibacterial drugs, Cleocin Phosphate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Contraindications

This drug is contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin.

Warnings

See WARNING box.

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Cleocin Phosphate, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

A careful inquiry should be made concerning previous sensitivities to drugs and other allergens.

This product contains benzyl alcohol as a preservative. The preservative benzyl alcohol has been associated with serious adverse events, including the "gasping syndrome", and death in pediatric patients. Although normal therapeutic doses of this product ordinarily deliver amounts of benzyl alcohol that are substantially lower than those reported in association with the "gasping syndrome", the minimum amount of benzyl alcohol at which toxicity may occur is not known. The risk of benzyl alcohol toxicity depends on the quantity administered and the hepatic capacity to detoxify the chemical. Premature and low birth weight infants may be more likely to develop toxicity.

Usage in Meningitis—Since clindamycin does not diffuse adequately into the cerebrospinal fluid, the drug should not be used in the treatment of meningitis.

SERIOUS ANAPHYLACTOID REACTIONS REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE. OXYGEN AND INTRAVENOUS CORTICOSTEROIDS SHOULD ALSO BE ADMINISTERED AS INDICATED.

Precautions

General

Review of experience to date suggests that a subgroup of older patients with associated severe illness may tolerate diarrhea less well. When clindamycin is indicated in these patients, they should be carefully monitored for change in bowel frequency.

Cleocin Phosphate products should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.

Cleocin Phosphate should be prescribed with caution in atopic individuals.

Certain infections may require incision and drainage or other indicated surgical procedures in addition to antibiotic therapy.

The use of Cleocin Phosphate may result in overgrowth of nonsusceptible organisms—particularly yeasts. Should superinfections occur, appropriate measures should be taken as indicated by the clinical situation.

Cleocin Phosphate should not be injected intravenously undiluted as a bolus, but should be infused over at least 10–60 minutes as directed in the DOSAGE AND ADMINISTRATION section.

Clindamycin dosage modification may not be necessary in patients with renal disease. In patients with moderate to severe liver disease, prolongation of clindamycin half-life has been found. However, it was postulated from studies that when given every eight hours, accumulation should rarely occur. Therefore, dosage modification in patients with liver disease may not be necessary. However, periodic liver enzyme determinations should be made when treating patients with severe liver disease.

Prescribing Cleocin Phosphate in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Information for Patients

Patients should be counseled that antibacterial drugs including Cleocin Phosphate should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Cleocin Phosphate is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Cleocin Phosphate or other antibacterial drugs in the future.

Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.

Laboratory Tests

During prolonged therapy periodic liver and kidney function tests and blood counts should be performed.

Drug Interactions

Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patients receiving such agents.

Antagonism has been demonstrated between clindamycin and erythromycin in vitro. Because of possible clinical significance, the two drugs should not be administered concurrently.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long term studies in animals have not been performed with clindamycin to evaluate carcinogenic potential. Genotoxicity tests performed included a rat micronucleus test and an Ames Salmonella reversion test. Both tests were negative.

Fertility studies in rats treated orally with up to 300 mg/kg/day (approximately 1.1 times the highest recommended adult human dose based on mg/m2) revealed no effects on fertility or mating ability.

In oral embryo fetal development studies in rats and subcutaneous embryo fetal development studies in rats and rabbits, no developmental toxicity was observed except at doses that produced maternal toxicity.

Pregnancy

Teratogenic effects

Pregnancy Category B

Oral and subcutaneous reproductive toxicity studies in rats and rabbits revealed no evidence of impaired fertility or harm to the fetus due to clindamycin, except at doses that caused maternal toxicity. Animal reproduction studies are not always predictive of human response.

In clinical trials with pregnant women, the systemic administration of clindamycin during the second and third trimesters, has not been associated with an increased frequency of congenital abnormalities.

Clindamycin should be used during the first trimester of pregnancy only if clearly needed. There are no adequate and well-controlled studies in pregnant women during the first trimester of pregnancy.

Cleocin Phosphate Sterile Solution contains benzyl alcohol. Benzyl alcohol can cross the placenta. See WARNINGS.

Nursing Mothers

Clindamycin has been reported to appear in breast milk in the range of 0.7 to 3.8 mcg/mL at dosages of 150 mg orally to 600 mg intravenously. Because of the potential for serious adverse reactions in nursing infants, clindamycin should not be taken by nursing mothers

Pediatric Use

When Cleocin Phosphate Sterile Solution is administered to the pediatric population (birth to 16 years) appropriate monitoring of organ system functions is desirable.

Usage in Newborns and Infants

This product contains benzyl alcohol as a preservative. Benzyl alcohol has been associated with a fatal "Gasping Syndrome" in premature infants. See WARNINGS.

The potential for the toxic effect in the pediatric population from chemicals that may leach from the single dose premixed IV preparation in plastic has not been evaluated.

Geriatric Use

Clinical studies of clindamycin did not include sufficient numbers of patients age 65 and over to determine whether they respond differently from younger patients. However, other reported clinical experience indicates that antibiotic-associated colitis and diarrhea (due to Clostridium difficile) seen in association with most antibiotics occur more frequently in the elderly (>60 years) and may be more severe. These patients should be carefully monitored for the development of diarrhea.

Pharmacokinetic studies with clindamycin have shown no clinically important differences between young and elderly subjects with normal hepatic function and normal (age-adjusted) renal function after oral or intravenous administration.

Adverse Reactions

The following reactions have been reported with the use of clindamycin.

Gastrointestinal

Antibiotic-associated colitis (see WARNINGS), pseudomembranous colitis, abdominal pain, nausea, and vomiting. The onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment (see WARNINGS). An unpleasant or metallic taste occasionally has been reported after intravenous administration of the higher doses of clindamycin phosphate.

Hypersensitivity Reactions

Maculopapular rash and urticaria have been observed during drug therapy. Generalized mild to moderate morbilliform-like skin rashes are the most frequently reported of all adverse reactions. Rare instances of erythema multiforme, some resembling Stevens-Johnson syndrome, have been associated with clindamycin. A few cases of anaphylactoid reactions have been reported. If a hypersensitivity reaction occurs, the drug should be discontinued. The usual agents (epinephrine, corticosteroids, antihistamines) should be available for emergency treatment of serious reactions. Acute Generalised Exanthematous Pustulosis (AGEP). Toxic epidermal necrolysis.

Skin and Mucous Membranes

Pruritus, vaginitis, and rare instances of exfoliative dermatitis have been reported (see Hypersensitivity Reactions).

Liver

Jaundice and abnormalities in liver function tests have been observed during clindamycin therapy.

Renal

Although no direct relationship of clindamycin to renal damage has been established, renal dysfunction as evidenced by azotemia, oliguria, and/or proteinuria has been observed in rare instances.

Hematopoietic

Transient neutropenia (leukopenia) and eosinophilia have been reported. Reports of agranulocytosis and thrombocytopenia have been made. No direct etiologic relationship to concurrent clindamycin therapy could be made in any of the foregoing.

Immune system

Drug reaction with eosinophilia and systemic symptoms (DRESS)

Local Reactions

Injection site irritation, pain, induration and sterile abscess have been reported after intramuscular injection and thrombophlebitis after intravenous infusion. Reactions can be minimized or avoided by giving deep intramuscular injections and avoiding prolonged use of indwelling intravenous catheters.

Musculoskeletal

Rare instances of polyarthritis have been reported.

Cardiovascular

Rare instances of cardiopulmonary arrest and hypotension have been reported following too rapid intravenous administration. (See DOSAGE AND ADMINISTRATION section.)

Overdosage

Significant mortality was observed in mice at an intravenous dose of 855 mg/kg and in rats at an oral or subcutaneous dose of approximately 2618 mg/kg. In the mice, convulsions and depression were observed.

Hemodialysis and peritoneal dialysis are not effective in removing clindamycin from the serum.

Cleocin Phosphate Dosage and Administration

If diarrhea occurs during therapy, this antibiotic should be discontinued (see WARNING box).

Clindamycin phosphate IM administration should be used undiluted.

Clindamycin phosphate IV administration should be diluted (See Dilution for IV use and IV infusion rates below)

Adults

Parenteral (IM or IV Administration): Serious infections due to aerobic gram-positive cocci and the more susceptible anaerobes (NOT generally including Bacteroides fragilis, Peptococcus species and Clostridium species other than Clostridium perfringens):

600–1200 mg/day in 2, 3 or 4 equal doses.

More severe infections, particularly those due to proven or suspected Bacteroides fragilis, Peptococcus species, or Clostridium species other than Clostridium perfringens:

1200–2700 mg/day in 2, 3 or 4 equal doses.

For more serious infections, these doses may have to be increased. In life-threatening situations due to either aerobes or anaerobes these doses may be increased. Doses of as much as 4800 mg daily have been given intravenously to adults. See Dilution for IV use and IV Infusion Rates section below.

Single intramuscular injections of greater than 600 mg are not recommended.

Alternatively, drug may be administered in the form of a single rapid infusion of the first dose followed by continuous IV infusion as follows:

To maintain serum clindamycin levels Rapid infusion rate Maintenance infusion rate
Above 4 mcg/mL 10 mg/min for 30 min 0.75 mg/min
Above 5 mcg/mL 15 mg/min for 30 min 1.00 mg/min
Above 6 mcg/mL 20 mg/min for 30 min 1.25 mg/min

Neonates (less than 1 month)

15 to 20 mg/kg/day in 3 to 4 equal doses. The lower dosage may be adequate for small prematures.

Pediatric patients 1 month of age to 16 years

Parenteral (IM or IV) Administration: 20 to 40 mg/kg/day in 3 or 4 equal doses. The higher doses would be used for more severe infections. As an alternative to dosing on a body weight basis, pediatric patients may be dosed on the basis of square meters body surface: 350 mg/m2/day for serious infections and 450 mg/m2/day for more severe infections.

Parenteral therapy may be changed to oral CLEOCIN PEDIATRIC® Flavored Granules (clindamycin palmitate hydrochloride) or CLEOCIN HCl® Capsules (clindamycin hydrochloride) when the condition warrants and at the discretion of the physician.

In cases of β-hemolytic streptococcal infections, treatment should be continued for at least 10 days.

Dilution for IV use and IV Infusion Rates

The concentration of clindamycin in diluent for infusion should not exceed 18 mg per mL. Infusion rates should not exceed 30 mg per minute. The usual infusion dilutions and rates are as follows:

Dose Diluent Time
300 mg 50 mL 10 min
600 mg 50 mL 20 min
900 mg 50–100 mL       30 min
1200 mg   100 mL 40 min

Administration of more than 1200 mg in a single 1-hour infusion is not recommended.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Dilution and Compatibility

Physical and biological compatibility studies monitored for 24 hours at room temperature have demonstrated no inactivation or incompatibility with the use of Cleocin Phosphate Sterile Solution (clindamycin phosphate) in IV solutions containing sodium chloride, glucose, calcium or potassium, and solutions containing vitamin B complex in concentrations usually used clinically. No incompatibility has been demonstrated with the antibiotics cephalothin, kanamycin, gentamicin, penicillin or carbenicillin.

The following drugs are physically incompatible with clindamycin phosphate: ampicillin sodium, phenytoin sodium, barbiturates, aminophylline, calcium gluconate, and magnesium sulfate.

The compatibility and duration of stability of drug admixtures will vary depending on concentration and other conditions. For current information regarding compatibilities of clindamycin phosphate under specific conditions, please contact the Medical and Drug Information Unit, Pharmacia & Upjohn Company (Division of Pfizer Inc).

Physico-Chemical Stability of diluted solutions of Cleocin Phosphate

Room temperature: 6, 9 and 12 mg/mL (equivalent to clindamycin base) in dextrose injection 5%, sodium chloride injection 0.9%, or Lactated Ringers Injection in glass bottles or minibags, demonstrated physical and chemical stability for at least 16 days at 25°C. Also, 18 mg/mL (equivalent to clindamycin base) in dextrose injection 5%, in minibags, demonstrated physical and chemical stability for at least 16 days at 25°C.

Refrigeration: 6, 9 and 12 mg/mL (equivalent to clindamycin base) in dextrose injection 5%, sodium chloride injection 0.9%, or Lactated Ringers Injection in glass bottles or minibags, demonstrated physical and chemical stability for at least 32 days at 4°C.

IMPORTANT: This chemical stability information in no way indicates that it would be acceptable practice to use this product well after the preparation time. Good professional practice suggests that compounded admixtures should be administered as soon after preparation as is feasible.

Frozen: 6, 9 and 12 mg/mL (equivalent to clindamycin base) in dextrose injection 5%, sodium chloride injection 0.9%, or Lactated Ringers Injection in minibags demonstrated physical and chemical stability for at least eight weeks at -10°C.

Frozen solutions should be thawed at room temperature and not refrozen.

DIRECTIONS FOR DISPENSING

Pharmacy Bulk Package — Not for Direct Infusion

The Pharmacy Bulk Package is for use in a Pharmacy Admixture Service only under a laminar flow hood. Entry into the vial should be made with a small diameter sterile transfer set or other small diameter sterile dispensing device, and contents dispensed in aliquots using aseptic technique. Multiple entries with a needle and syringe are not recommended. AFTER ENTRY USE ENTIRE CONTENTS OF VIAL PROMPTLY. ANY UNUSED PORTION MUST BE DISCARDED WITHIN 24 HOURS AFTER INITIAL ENTRY.

DIRECTIONS FOR USE

Cleocin Phosphate IV Solution in Galaxy Plastic Container

Premixed Cleocin Phosphate IV Solution is for intravenous administration using sterile equipment. Check for minute leaks prior to use by squeezing bag firmly. If leaks are found, discard solution as sterility may be impaired. Do not add supplementary medication. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Do not use unless solution is clear and seal is intact.

Caution: Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before administration of the fluid from the secondary container is complete.

Preparation for Administration:

  1. Suspend container from eyelet support.
  2. Remove protector from outlet port at bottom of container.
  3. Attach administration set. Refer to complete directions accompanying set.
Preparation of Cleocin Phosphate in ADD-Vantage System

For IV Use Only. Cleocin Phosphate 600 mg and 900 mg may be reconstituted in 50 mL or 100 mL, respectively, of dextrose injection 5% or sodium chloride injection 0.9% in the ADD-diluent container. Refer to separate instructions for ADD-Vantage‡ System.

How is Cleocin Phosphate Supplied

Each mL of Cleocin Phosphate Sterile Solution contains clindamycin phosphate equivalent to 150 mg clindamycin, 0.5 mg disodium edetate,; 9.45 mg benzyl alcohol added as preservative. When necessary, pH is adjusted with sodium hydroxide and/or hydrochloric acid. Cleocin Phosphate is available in the following packages:

25-2 mL vials NDC 0009-0870-26
25-4 mL vials NDC 0009-0775-26
25-6 mL vials NDC 0009-0902-18
5-60 mL Pharmacy Bulk Package NDC 0009-0728-09

Cleocin Phosphate is supplied in ADD-Vantage vials as follows:

NDC Vial Size Total Clindamycin Phosphate/vial Amount of Diluent
0009-3124-03 25-4 mL Vials 600 mg 50 mL
0009-3447-03 25-6 mL vials 900 mg 100 mL

Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP].

Cleocin Phosphate IV Solution in Galaxy plastic containers is a sterile solution of clindamycin phosphate with 5% dextrose. The single dose Galaxy plastic containers are available as follows:

24-300 mg/50 mL containers NDC 0009-3381-02
24-600 mg/50 mL containers NDC 0009-3375-02
24-900 mg/50 mL containers NDC 0009-3382-02

Exposure of pharmaceutical products to heat should be minimized. It is recommended that Galaxy plastic containers be stored at room temperature (25°C). Avoid temperatures above 30°C.

Animal Toxicology

One year oral toxicity studies in Spartan Sprague-Dawley rats and beagle dogs at dose levels up to 300 mg/kg/day (approximately 1.1 and 3.6 times the highest recommended adult human dose based on mg/m2, respectively) have shown clindamycin to be well tolerated. No appreciable difference in pathological findings has been observed between groups of animals treated with clindamycin and comparable control groups. Rats receiving clindamycin hydrochloride at 600 mg/kg/day (approximately 2.1 times the highest recommended adult human dose based on mg/m2) for 6 months tolerated the drug well; however, dogs dosed at this level (approximately 7.2 times the highest recommended adult human dose based on mg/m2) vomited, would not eat, and lost weight.

REFERENCES

  1. Smith RB, Phillips JP: Evaluation of CLEOCIN HCl and Cleocin Phosphate in an Aged Population. Upjohn TR 8147-82-9122-021, December 1982.
  2. CLSI. Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement. CLSI document M 100-S20. Wayne, PA: Clinical and Laboratory Standards Institute; 2010.
  3. CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard – Eighth Edition. CLSI document M07-A8. Wayne, PA: Clinical and Laboratory Standards Institute; 2009.
  4. CLSI. Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard - Tenth Edition. CLSI document M02-A10. Wayne, PA: Clinical and Laboratory Standards Institute; 2009.
  5. CLSI. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard-Seventh Edition. CLSI document M11-A7. Wayne, PA: Clinical and Laboratory Standards Institute; 2007.

ADD-Vantage® is a registered trademark of Hospira Inc.

Cleocin Phosphate IV Solution in the Galaxy plastic containers is manufactured for Pfizer Inc by Baxter Healthcare Corporation, Deerfield, IL 60015.

Galaxy® is a registered trademark of Baxter International Inc.

                          

LAB-0044-10.0
December 2013

Cleocin Phosphate®
clindamycin sterile solution for injection, USP
in ADD-Vantage® Vial

For Intravenous Use Only
NOT FOR INTRAMUSCULAR USE

INSTRUCTIONS FOR USE FOR ADD-VANTAGE SYSTEM—FOR IV USE ONLY

To Open Diluent Container:

Peel overwrap from the corner and remove container. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually.

To Assemble Vial and Flexible Diluent Container:

(Use Aseptic Technique)

  1. Remove the protective covers from the top of the vial and the vial port on the diluent container as follows:
    1. To remove the breakaway vial cap, swing the pull ring over the top of the vial and pull down far enough to start the opening (SEE FIGURE 1.), then pull straight up to remove the cap. (SEE FIGURE 2.) NOTE: Once the breakaway cap has been removed, DO NOT ACCESS VIAL WITH SYRINGE.
    2. To remove the vial port cover, grasp the tab on the pull ring, pull up to break the three tie strings, then pull back to remove the cover. (SEE FIGURE 3.)
  2. Screw the vial into the vial port until it will go no farther. THE VIAL MUST BE SCREWED IN TIGHTLY TO ASSURE A SEAL. This occurs approximately 1/2 turn (180°) after the first audible click. (SEE FIGURE 4.) The clicking sound does not assure a seal; the vial must be turned as far as it will go. NOTE: Once the vial is seated, do not attempt to remove it. (SEE FIGURE 4.)
  3. Recheck the vial to assure that it is tight by trying to turn it further in the direction of assembly.
  4. Label appropriately.

To Prepare Admixture:

  1. Squeeze the bottom of the diluent container gently to inflate the portion of the container surrounding the end of the drug vial.
  2. With the other hand, push the drug vial down into the container telescoping the walls of the container. Grasp the inner cap of the vial through the walls of the container. (SEE FIGURE 5.)
  3. Pull the inner cap from the drug vial. (SEE FIGURE 6.) Verify that the rubber stopper has been pulled out, allowing the drug and diluent to mix.
  4. Mix container contents thoroughly and use within the specified time.

Preparation for Administration: (Use Aseptic Technique)

  1. Confirm the activation and admixture of vial contents.
  2. Check for leaks by squeezing container firmly. If leaks are found, discard unit as sterility may be impaired.
  3. Close flow control clamp of administration set.
  4. Remove cover from outlet port at bottom of container.
  5. Insert piercing pin of administration set into port with a twisting motion until the pin is firmly seated. NOTE: See full directions on administration set carton.
  6. Lift the free end of the hanger loop on the bottom of the vial, breaking the two tie strings. Bend the loop outward to lock it in the upright position, then suspend container from hanger.
  7. Squeeze and release drip chamber to establish proper fluid level in chamber.
  8. Open flow control clamp and clear air from set. Close clamp.
  9. Attach set to venipuncture device. If device is not indwelling, prime and make venipuncture.
  10. Regulate rate of administration with flow control clamp.

WARNING: Do not use flexible container in series connections.

ADD-Vantage® is a registered trademark of Hospira Inc..

LAB-0050-4.0
October 2013

PRINCIPAL DISPLAY PANEL - 300 mg/2 mL Vial Label

2 mL Vial
NDC 0009-0870-21

Cleocin
Phosphate®

clindamycin injection, USP
300 mg/2 mL*
(150 mg/mL)

For intramuscular or intravenous use

Rx only

PRINCIPAL DISPLAY PANEL - 300 mg/2 mL Vial Carton

NDC 0009-0870-26
Contains 25 of NDC 0009-0870-21

25—2 mL Single Dose Vials

Cleocin Phosphate®
clindamycin injection, USP
300 mg/2 mL*
(150 mg/mL)

For intramuscular or intravenous use

Pfizer Injectables
Rx only

PRINCIPAL DISPLAY PANEL - 600 mg/4 mL Vial Label

4 mL Vial
NDC 0009-0775-20

Cleocin Phosphate®
clindamycin injection, USP
600 mg/4 mL*
(150 mg/mL)

For intramuscular or intravenous use

Rx only

PRINCIPAL DISPLAY PANEL - 600 mg/4 mL Vial Carton

NDC 0009-0775-26
Contains 25 of NDC 0009-0775-20

25—4 mL Single Dose Vials

Cleocin Phosphate®
clindamycin injection, USP
600 mg/4 mL*
(150 mg/mL)

For intramuscular or intravenous use

Pfizer Injectables

Rx only

PRINCIPAL DISPLAY PANEL - 900 mg/6 mL Vial Label

6 mL Vial
NDC 0009-0902-11

Cleocin Phosphate®
clindamycin injection, USP
900 mg/6 mL*
(150 mg/mL)

For intramuscular or intravenous use

Rx only

PRINCIPAL DISPLAY PANEL - 900 mg/6 mL Vial Carton

NDC 0009-0902-18
Contains 25 of NDC 0009-0902-11

25—6 mL Single Dose Vials

Cleocin Phosphate®
clindamycin injection, USP
900 mg/6 mL*
(150 mg/mL)

For intramuscular or intravenous use

Pfizer Injectables

Rx only

PRINCIPAL DISPLAY PANEL - 9,000 mg/60 mL Vial Bulk Label

NDC 0009-0728-05

60 mL Pharmacy
Bulk Package

Cleocin
Phosphate
®
clindamycin injection, USP
9,000 mg/60 mL*
(150 mg/mL)

For intramuscular or intravenous use
Not for direct infusion

Pfizer Injectables
Rx only

Distributed by Pharmacia & Upjohn Co
Division of Pfizer Inc, NY, NY 10017
MADE IN USA (includes foreign content)

PRINCIPAL DISPLAY PANEL - 9,000 mg/60 mL Vial Bulk Carton

NDC 0009-0728-09
Contains 5 of NDC 0009-0728-05

5—60 mL Pharmacy Bulk Packages

Cleocin Phosphate®
clindamycin injection, USP
9,000 mg/60 mL*
(150 mg/mL)

For intramuscular or intravenous use

Not for direct infusion

Pfizer Injectables
Rx only

PRINCIPAL DISPLAY PANEL - 600 mg/4 mL Vial Label

NDC 0009-3124-01

Single Dose
4 mL ADD-Vantage™ Vial

Cleocin Phosphate®
clindamycin injection, USP
600 mg/4 mL*
(150 mg/mL)

For intravenous use only

Use only with the ADD-Vantage diluent container.

Pfizer Injectables
Rx only

PRINCIPAL DISPLAY PANEL - 600 mg/4 mL Vial Carton

25—4 mL Single Dose
ADD-Vantage™ Vials

NDC 0009-3124-03
Contains 25 of NDC 0009-3124-01

Cleocin Phosphate®
clindamycin injection, USP
600 mg/4 mL*
(150 mg/mL)

For intravenous use only

Pfizer Injectables

Rx only

PRINCIPAL DISPLAY PANEL - 900 mg/6 mL Vial Label

NDC 0009-3447-01

Single Dose
6 mL ADD-Vantage™ Vial

Cleocin Phosphate®
clindamycin injection, USP
900 mg/6 mL*
(150 mg/mL)

For intravenous use only

Use only with the ADD-Vantage diluent container.

Pfizer Injectables
Rx only

PRINCIPAL DISPLAY PANEL - 900 mg/6 mL Vial Carton

25—6 mL Single Dose
ADD-Vantage™ Vials

NDC 0009-3447-03
Contains 25 of NDC 0009-3447-01

Cleocin Phosphate®
clindamycin injection, USP
900 mg/6 mL*
(150 mg/mL)

For intravenous use only

Pfizer Injectables
Rx only

PRINCIPAL DISPLAY PANEL - 300 mg/ 50 mL Container Label

NDC 0009-3381-01

Single Dose Container
Rx only

Cleocin Phosphate® IV Solution
clindamycin injection

300 mg/ 50 mL*
in 5% DEXTROSE

For Intravenous Use

Code 2G3414
Sterile, Nonpyrogenic

GALAXY

Recommended storage: Room temperature (25°C). Avoid temperatures above 30°C.
DOSAGE AND USE:
See accompanying prescribing information.
Not for rapid injection or IV push.
Cautions: Do not add supplementary medication. Must not be used in series
connections. Check for minute leaks and solution clarity.
* Each 50 mL contains clindamycin phosphate equivalent to 300 mg clindamycin
and 2.5 g dextrose hydrous, USP with 2 mg edetate disodium dihydrate,
USP added. pH adjusted with sodium hydroxide and/or hydrochloric acid.
Cleocin Phosphate is a registered trademark of
Pharmacia & Upjohn Company.
GALAXY is a trademark of Baxter International Inc.
Manufactured for Pfizer Inc by Baxter Healthcare
Corporation, Deerfield, IL 60015

Pfizer Injectables

Distributed by
Pharmacia & Upjohn Co
Division of Pfizer Inc
New York, NY 10017

PL 2501 Plastic
11152900
07-34-63-473
07-34-63-473
1865

PRINCIPAL DISPLAY PANEL - 300 mg/ 50 mL Container Carton

12 x 50 mL Single Dose Containers
Contains 12 of NDC 0009-3381-01

Cleocin Phosphate® IV Solution
clindamycin injection

Rx only

Pfizer Injectables

300 mg/ 50 mL*
in 5% Dextrose

NDC 0009-3381-02
Code 2G3414

PRINCIPAL DISPLAY PANEL - 600 mg/ 50 mL Container Label

NDC 0009-3375-01

Single Dose Container
Rx only

Cleocin Phosphate® IV Solution
clindamycin injection

600 mg/ 50 mL*
in 5% DEXTROSE

For Intravenous Use

Code 2G3415
Sterile, Nonpyrogenic

GALAXY

Recommended storage: Room temperature (25°C). Avoid temperatures above 30°C.
DOSAGE AND USE:
See accompanying prescribing information.
Not for rapid injection or IV push.
Cautions: Do not add supplementary medication. Must not be used in series
connections. Check for minute leaks and solution clarity.
* Each 50 mL contains clindamycin phosphate equivalent to 600 mg clindamycin
and 2.5 g dextrose hydrous, USP with 2 mg edetate disodium dihydrate,
USP added. pH adjusted with sodium hydroxide and/or hydrochloric acid.
Cleocin Phosphate is a registered trademark of
Pharmacia & Upjohn Company.
GALAXY is a trademark of Baxter International Inc.
Manufactured for Pfizer Inc by Baxter Healthcare
Corporation, Deerfield, IL 60015

Pfizer Injectables

Distributed by
Pharmacia & Upjohn Co
Division of Pfizer Inc
New York, NY 10017

PL 2501 Plastic
11153200
07-34-63-474
07-34-63-474
1864

PRINCIPAL DISPLAY PANEL - 600 mg/ 50 mL Container Carton

12 x 50 mL Single Dose Containers
Contains 12 of NDC 0009-3375-01

Cleocin Phosphate® IV Solution
clindamycin injection

Rx only

Pfizer Injectables

600 mg/ 50 mL*
in 5% Dextrose

NDC 0009-3375-02
Code 2G3415

PRINCIPAL DISPLAY PANEL - 900 mg/ 50 mL Container Label

NDC 0009-3382-01

Single Dose Container
Rx only

Cleocin Phosphate® IV Solution
clindamycin injection

900 mg/ 50 mL*
in 5% DEXTROSE

For Intravenous Use

Code 2G3416
Sterile, Nonpyrogenic

GALAXY

Recommended storage: Room temperature (25°C). Avoid temperatures above 30°C.
DOSAGE AND USE:
See accompanying prescribing information.
Not for rapid injection or IV push.
Cautions: Do not add supplementary medication. Must not be used in series
connections. Check for minute leaks and solution clarity.
* Each 50 mL contains clindamycin phosphate equivalent to 900 mg clindamycin
and 2.5 g dextrose hydrous, USP with 2 mg edetate disodium dihydrate,
USP added. pH adjusted with sodium hydroxide and/or hydrochloric acid.
Cleocin Phosphate is a registered trademark of
Pharmacia & Upjohn Company.
GALAXY is a trademark of Baxter International Inc.
Manufactured for Pfizer Inc by Baxter Healthcare
Corporation, Deerfield, IL 60015

Pfizer Injectables

Distributed by
Pharmacia & Upjohn Co
Division of Pfizer Inc
New York, NY 10017

PL 2501 Plastic
11153500
07-34-63-475
07-34-63-475
1866

PRINCIPAL DISPLAY PANEL - 900 mg/ 50 mL Container Carton

12 x 50 mL Single Dose Containers
Contains 12 of NDC 0009-3382-01

Cleocin Phosphate® IV Solution
clindamycin injection

Rx only

Pfizer Injectables

900 mg/ 50 mL*
in 5% Dextrose

NDC 0009-3382-02
Code 2G3416

Cleocin Phosphate 
clindamycin phosphate injection, solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0009-0870
Route of Administration INTRAMUSCULAR, INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
CLINDAMYCIN PHOSPHATE (CLINDAMYCIN) CLINDAMYCIN 150 mg  in 1 mL
Inactive Ingredients
Ingredient Name Strength
EDETATE DISODIUM 0.5 mg  in 1 mL
BENZYL ALCOHOL 9.45 mg  in 1 mL
SODIUM HYDROXIDE  
HYDROCHLORIC ACID  
Packaging
# Item Code Package Description
1 NDC:0009-0870-26 25 VIAL in 1 CARTON
1 NDC:0009-0870-21 2 mL in 1 VIAL
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA050441 10/02/1972
Cleocin Phosphate 
clindamycin phosphate injection, solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0009-0775
Route of Administration INTRAMUSCULAR, INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
CLINDAMYCIN PHOSPHATE (CLINDAMYCIN) CLINDAMYCIN 150 mg  in 1 mL
Inactive Ingredients
Ingredient Name Strength
EDETATE DISODIUM 0.5 mg  in 1 mL
BENZYL ALCOHOL 9.45 mg  in 1 mL
SODIUM HYDROXIDE  
HYDROCHLORIC ACID  
Packaging
# Item Code Package Description
1 NDC:0009-0775-26 25 VIAL in 1 CARTON
1 NDC:0009-0775-20 4 mL in 1 VIAL
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA050441 10/02/1972
Cleocin Phosphate 
clindamycin phosphate injection, solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0009-0902
Route of Administration INTRAMUSCULAR, INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
CLINDAMYCIN PHOSPHATE (CLINDAMYCIN) CLINDAMYCIN 150 mg  in 1 mL
Inactive Ingredients
Ingredient Name Strength
EDETATE DISODIUM 0.5 mg  in 1 mL
BENZYL ALCOHOL 9.45 mg  in 1 mL
SODIUM HYDROXIDE  
HYDROCHLORIC ACID  
Packaging
# Item Code Package Description
1 NDC:0009-0902-18 25 VIAL in 1 CARTON
1 NDC:0009-0902-11 6 mL in 1 VIAL
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA050441 10/02/1972
Cleocin Phosphate 
clindamycin phosphate injection, solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0009-0728
Route of Administration INTRAMUSCULAR, INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
CLINDAMYCIN PHOSPHATE (CLINDAMYCIN) CLINDAMYCIN 150 mg  in 1 mL
Inactive Ingredients
Ingredient Name Strength
EDETATE DISODIUM 0.5 mg  in 1 mL
BENZYL ALCOHOL 9.45 mg  in 1 mL
SODIUM HYDROXIDE  
HYDROCHLORIC ACID  
Packaging
# Item Code Package Description
1 NDC:0009-0728-09 5 VIAL, PHARMACY BULK PACKAGE in 1 CARTON
1 NDC:0009-0728-05 60 mL in 1 VIAL, PHARMACY BULK PACKAGE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA050441 10/02/1972
Cleocin Phosphate 
clindamycin phosphate injection, solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0009-3124
Route of Administration INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
CLINDAMYCIN PHOSPHATE (CLINDAMYCIN) CLINDAMYCIN 150 mg  in 1 mL
Inactive Ingredients
Ingredient Name Strength
EDETATE DISODIUM 0.5 mg  in 1 mL
BENZYL ALCOHOL 9.45 mg  in 1 mL
SODIUM HYDROXIDE  
HYDROCHLORIC ACID  
Packaging
# Item Code Package Description
1 NDC:0009-3124-03 25 VIAL in 1 CARTON
1 NDC:0009-3124-01 4 mL in 1 VIAL
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA062803 10/16/1987
Cleocin Phosphate 
clindamycin phosphate injection, solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0009-3447
Route of Administration INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
CLINDAMYCIN PHOSPHATE (CLINDAMYCIN) CLINDAMYCIN 150 mg  in 1 mL
Inactive Ingredients
Ingredient Name Strength
EDETATE DISODIUM 0.5 mg  in 1 mL
BENZYL ALCOHOL 9.45 mg  in 1 mL
SODIUM HYDROXIDE  
HYDROCHLORIC ACID  
Packaging
# Item Code Package Description
1 NDC:0009-3447-03 25 VIAL in 1 CARTON
1 NDC:0009-3447-01 6 mL in 1 VIAL
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA062803 10/16/1987
Cleocin Phosphate 
clindamycin phosphate injection, solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0009-3381
Route of Administration INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
CLINDAMYCIN PHOSPHATE (CLINDAMYCIN) CLINDAMYCIN 6 mg  in 1 mL
Inactive Ingredients
Ingredient Name Strength
EDETATE DISODIUM 0.4 mg  in 1 mL
DEXTROSE  
SODIUM HYDROXIDE  
HYDROCHLORIC ACID  
Packaging
# Item Code Package Description
1 NDC:0009-3381-02 2 CARTON in 1 PACKAGE
1 12 BAG in 1 CARTON
1 NDC:0009-3381-01 50 mL in 1 BAG
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA050639 08/30/1990
Cleocin Phosphate 
clindamycin phosphate injection, solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0009-3375
Route of Administration INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
CLINDAMYCIN PHOSPHATE (CLINDAMYCIN) CLINDAMYCIN 12 mg  in 1 mL
Inactive Ingredients
Ingredient Name Strength
EDETATE DISODIUM 0.4 mg  in 1 mL
DEXTROSE  
SODIUM HYDROXIDE  
HYDROCHLORIC ACID  
Packaging
# Item Code Package Description
1 NDC:0009-3375-02 2 CARTON in 1 PACKAGE
1 12 BAG in 1 CARTON
1 NDC:0009-3375-01 50 mL in 1 BAG
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA050639 08/30/1990
Cleocin Phosphate 
clindamycin phosphate injection, solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0009-3382
Route of Administration INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
CLINDAMYCIN PHOSPHATE (CLINDAMYCIN) CLINDAMYCIN 18 mg  in 1 mL
Inactive Ingredients
Ingredient Name Strength
EDETATE DISODIUM 0.4 mg  in 1 mL
DEXTROSE  
SODIUM HYDROXIDE  
HYDROCHLORIC ACID  
Packaging
# Item Code Package Description
1 NDC:0009-3382-02 2 CARTON in 1 PACKAGE
1 12 BAG in 1 CARTON
1 NDC:0009-3382-01 50 mL in 1 BAG
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA050639 08/30/1990
Labeler - Pharmacia and Upjohn Company (829076566)
Establishment
Name Address ID/FEI Operations
Zhejiang Hisoar Pharmaceutical Co., Ltd. 530736917 API MANUFACTURE(0009-3375, 0009-3381, 0009-3447, 0009-3124, 0009-0728, 0009-0902, 0009-0775, 0009-3382, 0009-0870)
Establishment
Name Address ID/FEI Operations
Pharmacia and Upjohn Company 829076566 ANALYSIS(0009-3447, 0009-3124, 0009-0728, 0009-0902, 0009-0775, 0009-0870), API MANUFACTURE(0009-3375, 0009-3381, 0009-3447, 0009-3124, 0009-0728, 0009-0902, 0009-0775, 0009-3382, 0009-0870), LABEL(0009-3447, 0009-3124, 0009-0728, 0009-0902, 0009-0775, 0009-0870), MANUFACTURE(0009-3447, 0009-3124, 0009-0728, 0009-0902, 0009-0775, 0009-0870), PACK(0009-3447, 0009-3124, 0009-0728, 0009-0902, 0009-0775, 0009-0870)
Establishment
Name Address ID/FEI Operations
Chongqing Carelife Pharmaceutical Co., Ltd 531132009 API MANUFACTURE(0009-3375, 0009-3381, 0009-3447, 0009-3124, 0009-0728, 0009-0902, 0009-0775, 0009-3382, 0009-0870)
Establishment
Name Address ID/FEI Operations
Baxter Healthcare Corporation 194684502 ANALYSIS(0009-3375, 0009-3381, 0009-3382), LABEL(0009-3375, 0009-3381, 0009-3382), MANUFACTURE(0009-3375, 0009-3381, 0009-3382), PACK(0009-3375, 0009-3381, 0009-3382)
Establishment
Name Address ID/FEI Operations
Pfizer Pharmaceuticals LLC 829084545 LABEL(0009-3447, 0009-3124), PACK(0009-3447, 0009-3124)
Revised: 12/2013
 
Pharmacia and Upjohn Company
Hide
(web4)